Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer

Radiother Oncol. 2009 Dec;93(3):654. doi: 10.1016/j.radonc.2009.05.005. Epub 2009 Jun 11.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Comment

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / radiotherapy
  • Cetuximab
  • Combined Modality Therapy
  • Dose Fractionation, Radiation
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / radiotherapy*
  • Humans
  • Middle Aged
  • Mucositis / etiology
  • Mucositis / pathology
  • Patient Compliance
  • Radiodermatitis / etiology
  • Radiodermatitis / pathology
  • Radiotherapy / adverse effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Cetuximab